Biden Administration Pause On Pending Trump-Era Rules Stalls FDA Cannabinoids Guidance Progress
Executive Summary
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.
You may also be interested in...
Failed NDI Notifications Suggest Futility Of Current US Position On Cannabinoids In Supplements
FDA's evaluation of NDI notifications for cannabinoids currently is pointless, say industry stakeholders asking for a rule exempting hemp-derived cannabinoids from the agency’s prohibition against using in dietary supplements any ingredient studied or approved for use as a drug.
US House Appropriators Have Little Left To Say About Allowing Cannabinoids In Supplements
Appropriation Committee’s report with FDA’s FY2022 funding bill appears to signal that other than getting something done, members have little to say about establishing lawful use of hemp-derived cannabinoids in non-drug products.
Mixing Food In Legislation Changing US FDA Cannabinoid Rules Could Choke Its Progress
Making lawful the use of hemp cannabinoids in supplements and food is a step in the right direction, but including food may doom it, say industry stakeholders. As well, CRN CEO Steve Mister notes FDA has stated reservations about using cannabinoids in food.